Abstract
Ceftriaxone is a new semisynthetic cephalosporin with a very long serum half-life and broad coverage against Enterobacteriaceae and Pseudomonas aeruginosa. Clinical and microbiological efficacies were evaluated in 51 infections occurring in 46 patients: 20 pneumonias, 19 urinary tract infections, seven soft-tissue infections, two septic arthritis infections, two primary bacteremias and one otitis media. The usual dose of ceftriaxone was one gram every 12 hours. Improvement of cure occurred in 92% of infections; microbiological cure occurred in 93% of infections. A mild rise in liver function tests occurred in 14% of the 51 infections but was not thought clinically significant.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 574-581 |
| Number of pages | 8 |
| Journal | Current Therapeutic Research - Clinical and Experimental |
| Volume | 36 |
| Issue number | 3 |
| State | Published - 1984 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)